Abstract
BackgroundEpratuzumab is a monoclonal antibody that targets CD22 on B cells. In EMBLEM™ (dose-ranging Phase 2b study [NCT00624351]), and its open-label extension (OLE; SL0008 [NCT00660881]), epratuzumab produced sustained and clinically...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have